Provided by Tiger Trade Technology Pte. Ltd.

NT PHARMA

0.475
+0.09525.00%
Volume:988.25K
Turnover:489.29K
Market Cap:450.78M
PE:-11.25
High:0.550
Open:0.450
Low:0.450
Close:0.380
52wk High:1.350
52wk Low:0.300
Shares:949.00M
HK Float Shares:949.00M
Volume Ratio:1.08
T/O Rate:0.10%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.042
ROE:-8.14%
ROA:-1.76%
PB:-3.47
PE(LYR):-11.25
PS:10.78

Loading ...

NT PHARMA Plans to Divest Partial or Full Stake in Overseas Subsidiary

Stock News
·
May 29

NT Pharma Independent Non-Executive Director Resigns over Governance and Disclosure Disputes

Bulletin Express
·
May 20

China NT Pharma board disputes ex-director’s claims, reviews issues raised

Reuters
·
May 20

NT Pharma clarifies director’s judicial records after RMB119.00 million loan fully settled

Bulletin Express
·
May 15

China NT Pharma says RMB 119 million loan dispute debt fully repaid in restructuring

Reuters
·
May 15

China NT Pharma files directors list with Hong Kong Stock Exchange

Reuters
·
May 12

NT Pharma Discloses Historical Rule Breaches on Share Pledges and Related-Party Loans; Transactions Resolved and Control Measures Strengthened

Bulletin Express
·
May 11

China NT Pharma chairman faces PRC consumption restriction orders tied to subsidiary disputes

Reuters
·
May 11

NT Pharma appoints Kwok Che Chung as Independent Director and Audit Committee Chair, replacing Ng Ming Kwan

Bulletin Express
·
May 08

NT Pharma admits historical breaches over share pledges and shareholder loans; HK$362.20 million redemption still outstanding

Bulletin Express
·
May 08

NT PHARMA Appoints Guo Zhicong as Independent Non-Executive Director

Stock News
·
May 08

China NT Pharma names Kwok Che Chung independent director, audit committee chair

Reuters
·
May 08

China NT Pharma chairman faces PRC court consumption restrictions tied to subsidiary debts

Reuters
·
May 08

NT Pharma Reports Progress on AI Health Pivot, Debt Restructuring, and Auditor Disclaimer Resolution

Bulletin Express
·
Apr 30

NT Pharma Sets 4 June 2026 AGM; Shareholders to Decide on 20% Issuance Mandate, 10% Buy-back Authority and Board Re-elections

Bulletin Express
·
Apr 30

NT Pharma Schedules 4 June 2026 AGM; Proposes 20% Issuance Mandate, 10% Buy-back Limit and HK$0.75–0.85 Million Audit Fee

Bulletin Express
·
Apr 30

NT Pharma Publishes FY 2025 Annual Report, Circular and AGM Notice

Bulletin Express
·
Apr 30

NT PHARMA深化“AI+医疗”转型:2025年收入降至0.24亿元,亏损同比收窄

Bulletin Express
·
Apr 30

China NT Pharma announces annual general meeting

Reuters
·
Apr 30

China NT Pharma publishes 2025 annual report

Reuters
·
Apr 30